Mylan-Dexrazoxane 250 mg powder for Injection (US-labelled)
Due to a shortage in Canada, Pfizer Canada ULC has informed Health Canada that a steady supply of its ZINECARD (Dexrazoxane for Injection) is not expected until January 31, 2021. Given the medical necessity of this product, Health Canada has expressed no objection to the temporary importation and distribution of US-labelled Mylan-Dexrazoxane for Injection.
To assist healthcare professionals and patients avoid exposure to Divalproex during pregnancy, please review the following educational materials as part of the Pregnancy Prevention Program.
For more information, visit Mylan-Divalproex, Product Catalogue
Health Canada has deemed Mylan-Fingolimod bioequivalent to Gilenya®.
Mylan-Fingolimod Patient Support Program:
Download the Enrollment form here
Mylan-Fingolimod Pregnancy Registry
Phone 1-888-246-5830; Fax 1-833-677-0484